Nestle Health Science, like other companies in the nutritional space, offers products containing ingredients derived from peanuts. Unlike its competitors, its parent firm is acquiring a drug that could make peanut-containing products part of more consumers’ diets.
Confections, food and nutritional products giant Nestle SA is acquiring all shares of Aimmune Therapeutics Inc., other than shares Nestle Health Science already owns, under an agreement announced on 31 August
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?